That was yesterday
GlaxoSmithKline is to reintroduce performance-based bonuses linked to the number of prescriptions written for its medicines, reversing a company ban on the practice following a bribery scandal in the US….
The company was fined $3bn in 2012 after it admitted bribing doctors to write extra prescriptions for some products. As part of the settlement with US authorities, the drugmaker agreed it would no longer pay reps according to the number of prescriptions generated. That agreement has since lapsed.
Direct URL for this post.